However, side effects were more common, with 70.1 percent of participants having local reactions like redness and swelling compared to 43.1 percent of the control group, and 5.6 percent of the mRNA participants having a fever compared to just 1.7 percent with the non-mRNA version
One mistake during lunch was introducing it in lower dose These meds aren't for fat loss
The incremental number of QALYs associated with SGLT2i use was projected at 29,357, and widespread use of SGLT2is was projected to lead to an incremental healthcare cost of AU$0.3 billion, resulting in an ICER of AU$8878 per QALY gained
A subset of users report sleep changes with evening injections, describing either enhanced sleep quality or occasional restlessness
This metabolic adaptationa drop in resting metabolic rateis a normal physiological response, not medication failure